Cloning and expression of recombinant scFV monoclonal antibody against Carcinoembryonic antigen

Recombinant antibody technology has revolutionized the production and use of these kinds of antibodies and removed some of the hybridoma technology limitations. Monoclonal antibodies have high potential as diagnostic and therapeutic agents, especially in targeting cancer cells, but their use has been limited due to their large size. The special structure of different regions of antibodies allows to divide them into efficient subunits, which can combine to form new molecules with efficient properties. Due to the reduced size of scFv molecules compared to the primary antibody, they have many advantage. The most important of which is the reduction of immune compare to complete mouse antibodies due to the lack of constant fragments. In this study, the variable regions of gene carcinoembryonic tumor marker monoclonal antibody were constructed as scFV and cloned into the phagemid vector. Then its specificity was investigated by the western blotting test. The scFV gene was successfully constructed. Then cloning and expression was performed. Finally, its specificity was confirmed by western blotting. The recombinant scFV antibody expressed in this study, due to size change, was able to specifically identify the carcinoembryonic tumor marker, and therefore it can be used in the diagnosis of some cancers. This recombinant antibody was specifically capable of carcinoembryonic tumor marker recognition. Therefore, it can be applied to some cancers diagnosis and monitoring. In addition, this method can be used to synthesize scFV-type recombinant antibodies against other antigens. So that they can be used in various diagnostic tests and treatment most of diseases.